Results 21 to 30 of about 3,811,568 (245)

Nonmetastatic Castration-Resistant Prostate Cancer [PDF]

Korean Journal of Urology, 2014
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation.
Hong, Jun Hyuk, Kim, Isaac Y.
openaire   +2 more sources

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. [PDF]

, 2013
BACKGROUND: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
J S de Bono, Pezaro, C., Cassidy, A.M., de Bono, J.S., Pezaro, C, Seed, G., Mukherji, D, de Bono, JS, Omlin, A, Tunariu, N., N Tunariu, G Attard, D Olmos, Attard, G, G Seed, Reid, A.H.M., Seed, G, Mukherji, D., A M Cassidy, Bianchini, D., Cassidy, AM, Olmos, D., A H M Reid, Attard, G., A Omlin, D Bianchini, D Mukherji, Tunariu, N, Olmos, D, Reid, AHM, C Pezaro, Bianchini, D, Omlin, A.   +32 more
core   +1 more source

Bad expression influences time to androgen escape in prostate cancer [PDF]

, 2007
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Teo, K., Traynor, P., Mukherjee, R., Edwards, J., Gemmell, L.   +4 more
core   +1 more source

EP300-Mediated MTF1-K218 Lactylation Buffers AR-Driven Copper Overload to Suppress Cuproptosis in Castration-Resistant Prostate Cancer. [PDF]

Adv Sci (Weinh)
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Li K, Wei Y, Li Y, Dong Y, Lv J, Yuan M, Shen A, Liu F, Zhang Y, Li Y, Yu R, Liu Y, Zhao T, Wang J, Zhou K, Fan Z, Wang M, Xu J, Du M, Gu M, Yao B, Zhu Q.   +21 more
europepmc   +2 more sources

Visceral Disease in Castration-resistant Prostate Cancer [PDF]

European Urology, 2014
Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%.
Pezaro C. J., Omlin A., Lorente D., Nava Rodrigues D., Ferraldeschi R., Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., De Bono J. S., Attard G.   +12 more
openaire   +3 more sources

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

Ablative radiotherapy in castration-resistant prostate cancer. [PDF]

BJU Int
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC.   +9 more
europepmc   +2 more sources